Franklin Biolabs Achieves CLIA Certification for AAV NAb Testing
Learn more

High-Sensitivity ddPCR Assays for Quantifying Low-Level Biodistribution of CAR-T Cells

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

High-Sensitivity ddPCR Assays for Quantifying Low-Level Biodistribution of CAR-T Cells

High-Sensitivity ddPCR for CAR-T Biodistribution Studies

CELL & GENE | RNA | BIOLOGICS

Frequently Asked Questions (FAQ)

    What is the typical Lower Limit of Quantification (LLOQ) for a CAR-T ddPCR assay?

    Our validated ddPCR assays are designed to achieve high sensitivity, with the LLOQ optimized for each program based on the specific transgene sequence and tissue matrix. This approach enables robust detection and quantification of low-level cell persistence.

    How does the assay design mitigate risks of detecting non-viable cells?

    Our standard workflow quantifies CAR transgene DNA, which can persist transiently after cell death. For programs requiring confirmation of viable cell engraftment, we can develop a parallel reverse transcription ddPCR (RT-ddPCR) assay to quantify CAR mRNA. Detecting the transcript provides strong evidence of transcriptionally active, viable cells within a given tissue.

    Which tissues are included in a standard non-target tissue biodistribution panel?

    A typical panel is designed to meet regulatory expectations and includes a representative set of major organs and systems. Panels are customized in consultation with a program’s specific toxicology plan and the known biology of the CAR target.

    Can ddPCR differentiate between the therapeutic CAR-T cells and endogenous T-cells?

    Yes. The assay’s specificity is derived from primers and probes designed to target a unique sequence within the CAR construct itself (e.g., the linker or hinge region). This design ensures that the assay only amplifies and quantifies the genetically modified therapeutic cells, not the endogenous T-cell population.

Executive Summary

Digital droplet PCR (ddPCR) provides the absolute, high-sensitivity quantification required to accurately assess the persistence and non-target tissue biodistribution of Chimeric Antigen Receptor (CAR) T-cells. For cell therapy developers, precisely measuring low copy numbers of the CAR transgene in various tissues is a regulatory expectation for a complete safety profile. Unlike qPCR, ddPCR partitions samples into thousands of nanoliter-sized droplets, enabling direct counting of target DNA molecules without reliance on a standard curve. This method delivers the precision needed to de-risk clinical development and support a robust IND submission package.

A marketing flyer for Franklin Biolabs detailing their immunogenicity services, including various assays and support for cell and gene therapy clinical trials.

A scientist in a sterile laboratory setting uses a multichannel pipette to transfer pink liquid into a multi-well plate for a high-throughput experiment.

The Challenge: Quantifying Low-Level CAR-T Cell Engraftment

Assessing the long-term persistence and potential trafficking of CAR-T cells to non-target tissues is fundamental to building a comprehensive preclinical safety package. Following administration, the engineered cells may persist at extremely low levels, often falling below the reliable quantification limits of traditional qPCR-based methods. This presents a significant analytical challenge: failure to accurately detect and quantify low-copy-number cells can obscure the true biodistribution profile, potentially masking safety signals or misrepresenting long-term engraftment kinetics.

This need for ultra-sensitive and validated bioanalytical methods is a consistent theme in advanced therapy development. For instance, the successful validation of high-sensitivity assays to measure biomarkers in challenging matrices like cerebrospinal fluid and serum has been shown to be a key enabler for gene replacement therapy programs (PMID: 39282076). The core principle of establishing robust analytical performance for low-abundance targets directly translates to the challenges of CAR-T biodistribution.

Method Comparison: ddPCR vs. qPCR for Biodistribution

For quantifying CAR-T persistence, ddPCR offers distinct technical advantages over qPCR, particularly for meeting the stringent requirements of regulatory submissions. The platform’s ability to deliver absolute quantification removes the variability associated with standard curves, providing higher precision and day-to-day reproducibility.

Feature Droplet Digital PCR (ddPCR) Quantitative PCR (qPCR)
Quantification Absolute (direct molecule count) Relative (requires standard curve)
Precision High; less susceptible to PCR inhibitors Moderate; sensitive to inhibitor presence
Sensitivity Superior for low-copy number targets Limited by standard curve LLOQ
Regulatory View Preferred for vector copy number & biodistribution Accepted, but with known limitations
Workflow Requires droplet generation step Simpler, direct amplification

A blue-toned image of white lab rats in their cages within a laboratory or vivarium setting, likely for scientific research or testing.

GxP-Compliant Assay Development and Validation

Franklin Biolabs develops and validates custom ddPCR assays within a GxP framework to support IND-enabling studies. Our process ensures that each assay meets rigorous performance standards for specificity, sensitivity, precision, and accuracy. This level of documentation and validation is designed to withstand regulatory scrutiny.

Our bioanalytical and toxicology programs are conducted in a >100,000 sq ft facility, providing the scale and infrastructure for complex study designs and contributing to a standard 18-24 month IND timeline. The Franklin Biolabs brand launched in 2024, building on our core scientific team’s track record of maintaining a 100% IND success rate for client programs since 2019. All in vivo studies are conducted with strict adherence to Animal Welfare principles, including the 3Rs (Replacement, Reduction, and Refinement).

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities